Sunscreen labels may still be confusing to majority of consumers
the ONA take:
According to results of a small study published online ahead of print in JAMA Dermatology, researchers have found that sunscreen labels may still be confusing to the majority of consumers.
For the study, researchers from Northwestern University Feinberg School of Medicine in Chicago surveyed 114 patients at a single dermatology clinic to evaluate their understanding of sunscreen labels and best practices for sun protection.
Results showed that 81.6% reported purchasing sunscreen in 2013. Of all participants, 75.4% said they purchased sunscreen in order to prevent sunburns and 65.8% bought it to prevent skin cancer.
Researchers found that only 43% understood the definition of SPF, 37.7% could correctly determine how well the sunscreen protected against skin cancer, and 22.8% could correctly identify how well the sunscreen protected against sunburns.
The findings suggest that sunscreen label terminology may still be confusing to the majority of consumers seeking to protect themselves from sunburns and skin cancer.
Sunscreen labels may still be confusing to the majority of consumers.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|